Payment overview · 2025
General Payments
$116.93
6 reported records · 3 companies
Healthcare provider profile · identity verified
Adam Robert Klang, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BAKERSFIELD, CA · NPI 1386732246
Verified facts
What the public records show
CMS Open Payments records show Adam Robert Klang, MD received $116.93 in general payments during 2025 across 6 reported records.
Novo Nordisk Inc accounted for 69.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.02 | 69.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.43 | 16.6% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $16.48 | 14.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $116.93 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $53.26 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $16.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
20 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1012 | 171 |
| Pantoprazole Sodium | Pantoprazole Sodium | 567 | 126 |
| Furosemide | Furosemide | 532 | 110 |
| Gabapentin | Gabapentin | 508 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 497 | 93 |
| Metoprolol Tartrate | Metoprolol Tartrate | 477 | 51 |
| Eliquis | Apixaban | 353 | 62 |
| Potassium Chloride | Potassium Chloride | 348 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 305 | 51 |
| Omeprazole | Omeprazole | 293 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 287 | 56 |
| Metformin Hcl | Metformin Hcl | 265 | 49 |
| Mirtazapine | Mirtazapine | 230 | 38 |
| Famotidine | Famotidine | 219 | 78 |
| Amiodarone Hcl | Amiodarone Hcl | 204 | 29 |
| Lisinopril | Lisinopril | 184 | 60 |
| Midodrine Hcl | Midodrine Hcl | 181 | 41 |
| Carvedilol | Carvedilol | 170 | 48 |
| Allopurinol | Allopurinol | 166 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 20 |
| Memantine Hcl | Memantine Hcl | 161 | 16 |
| Levetiracetam | Levetiracetam | 157 | 29 |
| Januvia | Sitagliptin Phosphate | 155 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 150 | suppressed |
| Losartan Potassium | Losartan Potassium | 143 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 119 | 37 |
| Donepezil Hcl | Donepezil Hcl | 115 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 98 | 22 |
| Sertraline Hcl | Sertraline Hcl | 97 | 21 |
| Sucralfate | Sucralfate | 83 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 81 | 46 |
| Trazodone Hcl | Trazodone Hcl | 81 | 20 |
| Finasteride | Finasteride | 80 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 80 | 26 |
| Buspirone Hcl | Buspirone Hcl | 78 | 16 |
| Celecoxib | Celecoxib | 77 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 72 |
| Baclofen | Baclofen | 75 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 24 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 36 |
| Xarelto | Rivaroxaban | 67 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 63 | 25 |
| Cephalexin | Cephalexin | 58 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 58 | suppressed |
| Simvastatin | Simvastatin | 58 | suppressed |
| Bumetanide | Bumetanide | 57 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 57 | suppressed |
| Risperidone | Risperidone | 57 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 56 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | suppressed |
| Primidone | Primidone | 55 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 53 | suppressed |
| Methotrexate | Methotrexate Sodium | 53 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 52 | 11 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 52 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 50 | 25 |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 45 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 45 | 22 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Valproic Acid | Valproic Acid | 38 | suppressed |
| Insulin Lispro | Insulin Lispro | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | 14 |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 35 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Carbamazepine | Carbamazepine | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 28 |
| Lactulose | Lactulose | 33 | 30 |
| Amantadine | Amantadine Hcl | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 22 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 30 | suppressed |
| Pregabalin | Pregabalin | 29 | 21 |
| Prednisone | Prednisone | 28 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | 16 |
| Latanoprost | Latanoprost | 27 | 16 |
| Lorazepam | Lorazepam | 27 | 17 |
| Nystatin | Nystatin | 26 | 22 |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Spironolactone | Spironolactone | 25 | 15 |
| Lubiprostone | Lubiprostone | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Clonazepam | Clonazepam | 20 | 11 |
| Jardiance | Empagliflozin | 20 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 19 | 17 |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | 11 |
| Calcitriol | Calcitriol | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | 15 |
| Hydrocortisone | Hydrocortisone | 15 | 14 |
| Meloxicam | Meloxicam | 15 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Calcium Acetate | Calcium Acetate | 14 | suppressed |
| Constulose | Lactulose | 14 | 14 |
| Levofloxacin | Levofloxacin | 14 | 12 |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 14 | 12 |
| Azithromycin | Azithromycin | 13 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Narcan | Naloxone Hcl | 12 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $116.93 · 6 records | Novo Nordisk Inc | MOUNJARO, Ozempic, Rybelsus, UZEDY, Wegovy, ZEPBOUND | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error